Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Audrey Y Chang, Farrah J Mateen · 2026

Read Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review by Audrey Y Chang, Farrah J Mateen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655708.txt.

Description

Audrey Chang and Farrah Mateen wrote this 2026 narrative review on the diabetes and weight-loss drugs known as GLP-1 receptor agonists, and what they mean for people with multiple sclerosis. MS patients commonly carry exactly the conditions these drugs treat: obesity, diabetes, sleep apnea, fatty liver, and kidney disease. Prescriptions in this population are climbing fast.

The review works through three questions. Can these drugs deliver weight loss safely in MS patients, whose tolerance and mobility issues complicate therapy? Do they still work for their approved purposes in this group? And beyond those uses, might they protect the nervous system itself and slow the disease? The authors gather the early evidence on all three, flagging where data are thin. Their audience is the MS clinician now fielding patient questions about a famous drug class with an unproven second act.

Catalog record

CREATORAudrey Y Chang, Farrah J Mateen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13655708

Browse the full library · About the Tower of Babel